NovelStem Increases NewStem Ownership to 33% as NewStem Prepares for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares
BOCA RATON, Fla. and JERUSALEM, Dec. 01, 2020 (GLOBE NEWSWIRE) -- NovelStem International Corp.(OTC Pink: NSTM), a biotechnology company focused on its stem cell-based technology platform, developed...